GLOW

Typical use cases

Dosing guidelines

Titration

Some community protocols begin at a lower fraction of the daily dose and build up over the first days to assess tolerance; this is anecdotal rather than clinically validated.

Reconstitution

Reconstitute the lyophilized blend (commonly a 70 mg vial: ~50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157) with bacteriostatic water — e.g., 1 mL yields GHK-Cu 50 mg/mL, TB-500 10 mg/mL, BPC-157 10 mg/mL; 2-3 mL gives proportionally lower concentrations. Bacteriostatic water (with 0.9% benzyl alcohol) is generally preferred over normal saline because chloride ions can compete for copper coordination and may degrade the GHK-Cu chelate. Swirl gently rather than shaking.

Injection sites

Subcutaneous injection, commonly into abdominal subcutaneous fat (rotating sites); some community protocols also use sites near the area of interest.

Storage & handling

Store lyophilized vials frozen at approximately -20 °C; after reconstitution refrigerate at 2-8 °C and use within about 4 weeks. Protect from light and avoid repeated freeze-thaw.

Side effects

• Injection-site reaction (redness, swelling, itching) Mild · Common
• Nausea (notably with the BPC-157 component, dose-dependent) Mild · Uncommon
• Headache Mild · Uncommon
• Fatigue or drowsiness Mild · Uncommon
• Dizziness Mild · Rare
• Transient muscle discomfort (early TB-500 use) Mild · Rare

Research summary

GLOW is a co-formulated blend of three peptides rather than a single molecule, so its rationale rests on the overlapping but distinct evidence bases of its components. BPC-157, a synthetic gastric pentadecapeptide, has an extensive rodent literature reporting accelerated tendon, muscle, ligament, nerve, and gut healing; mechanistically it has been described to modulate angiogenesis via VEGFR2-PI3K-Akt-eNOS and Src-caveolin-1-eNOS pathways and to engage cytoprotective signaling, but human controlled trials are essentially absent and recent reviews stress it should be regarded as investigational. TB-500 is a synthetic peptide based on the actin-binding region of thymosin beta-4 (Tβ4), a 43-residue actin-sequestering protein implicated in cell migration, angiogenesis, anti-inflammatory signaling, and progenitor-cell recruitment; most regenerative data again derive from animal and in-vitro models, with full-length Tβ4 reaching some human trials. GHK-Cu is a naturally occurring copper-binding tripeptide (GHK) chelated to Cu2+ and has the most mature evidence of the three, including decades of cosmetic and wound-healing use; at nanomolar concentrations it has been reported to stimulate collagen and glycosaminoglycan synthesis, modulate matrix metalloproteinases, and broadly alter human gene expression. Important limitations apply: the combined GLOW blend itself has no dedicated clinical trial data, none of the components is FDA-approved for these uses, dosing is drawn from community/research protocols rather than validated human pharmacokinetics, and BPC-157 and TB-500 are prohibited in competitive sport by WADA. Reported tolerability is generally favorable in the available literature, but long-term human safety remains uncharacterized.

Key references

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
• https://pubmed.ncbi.nlm.nih.gov/20388964/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
• https://www.nature.com/articles/s41598-020-74022-y
• https://pubmed.ncbi.nlm.nih.gov/16099219/
• https://www.mdpi.com/2079-9284/5/2/29

Related compounds